Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
Cancer is the second leading cause of death in the United States with 1.7 million new cases estimated to be diagnosed in 2016. This disease remains a formidable clinical challenge and represents a substantial financial burden to the US health care system. Therefore, research and development of novel...
Main Authors: | Daniel A. Ladin, Eman Soliman, LaToya Griffin, Rukiyah Van Dross-Anderson |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00361/full |
Similar Items
-
Corrigendum: Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
by: Daniel A. Ladin, et al.
Published: (2021-07-01) -
Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms
by: Ken Soderstrom, et al.
Published: (2017-10-01) -
The potential role of cannabinoids in dermatology
by: Tabrez Sheriff, et al.
Published: (2020-11-01) -
The Endocannabinoid System, Cannabinoids, and Pain
by: Perry G. Fine, et al.
Published: (2013-10-01) -
The effect of cannabinoids on wound healing: A review
by: Aniruddha C. Parikh, et al.
Published: (2024-02-01)